VanEck Biotech ETF (NASDAQ:BBH) Short Interest Update

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,700 shares, an increase of 112.5% from the December 31st total of 800 shares. Based on an average daily trading volume, of 9,000 shares, the short-interest ratio is currently 0.2 days.

VanEck Biotech ETF Price Performance

Shares of VanEck Biotech ETF stock traded up $1.29 on Thursday, reaching $165.04. The company had a trading volume of 6,285 shares, compared to its average volume of 11,878. The firm’s 50 day moving average price is $161.94 and its two-hundred day moving average price is $171.01. VanEck Biotech ETF has a 52-week low of $151.35 and a 52-week high of $183.64.

VanEck Biotech ETF Announces Dividend

The company also recently declared a dividend, which was paid on Tuesday, December 24th. Stockholders of record on Monday, December 23rd were given a dividend of $1.2517 per share. The ex-dividend date of this dividend was Monday, December 23rd.

Institutional Investors Weigh In On VanEck Biotech ETF

A number of institutional investors have recently modified their holdings of the company. Truist Financial Corp boosted its holdings in VanEck Biotech ETF by 3.8% in the second quarter. Truist Financial Corp now owns 2,703 shares of the company’s stock valued at $455,000 after purchasing an additional 100 shares during the period. Kovitz Investment Group Partners LLC increased its position in shares of VanEck Biotech ETF by 4.6% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 3,186 shares of the company’s stock valued at $565,000 after purchasing an additional 141 shares during the last quarter. Flagship Harbor Advisors LLC raised its holdings in shares of VanEck Biotech ETF by 12.1% in the 4th quarter. Flagship Harbor Advisors LLC now owns 1,984 shares of the company’s stock valued at $311,000 after purchasing an additional 214 shares in the last quarter. Truvestments Capital LLC acquired a new stake in shares of VanEck Biotech ETF in the 3rd quarter valued at $44,000. Finally, FSA Wealth Management LLC purchased a new stake in shares of VanEck Biotech ETF during the 3rd quarter worth $54,000. 32.05% of the stock is owned by institutional investors and hedge funds.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.